(509) 228-1000 WA
(208) 754-3100 ID

Clinical Studies

TRIAL NUMBER - NCT03898180

The purpose of this study is to evaluate the efficacy and safety of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, or in participants ineligible for any platinum-containing chemotherapy regardless of CPS, with advanced/unresectable or metastatic urothelial carcinoma (UC).

 
I Want to Participate

Wondering if you qualify as a candidate for this trial? Visit the "View Trial" button below and print the the trial's details to discuss with your Cancer Care Northwest physician. 

View Trial

For More Information
If you are interested in this clinical trial, please email the Cancer Care Northwest Research Department at research@ccnw.net for more information. Be sure to include:

  • Your name
  • Phone number & if we can leave a voice message at this number
  • Trial number(s) you are interested in
  • Name and city of clinic you are currently being treated